미국 · 보도자료 · Phathom Pharmaceuticals · 2026-09-29 12:00
보퀘즈나, 비미란성 역류성 식도염 등록 임상 3상 착수
FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases, today announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing r
Phathom Pharmaceuticals 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
